
Investors should prioritize a "Long GLP-1, Short AI" strategy, as weight-loss drugs are currently viewed as undervalued compared to overhyped technology stocks. Focus on market leaders Novo Nordisk (NVO) and Eli Lilly (LLY) as they expand treatments into cardiovascular health, kidney disease, and sleep apnea. With J.P. Morgan projecting 25 million users by 2030, these pharmaceutical giants are positioned to benefit from a massive shift in global healthcare spending. Beyond biotech, look for investment opportunities in affordable elder care and specialized assisted living housing to serve the growing "Sandwich Generation." For individual financial planning, maximize income potential between ages 30 and 45 to hedge against future ageism and the rising costs of family care.

By @theprofgpod
NYU Professor, best-selling author, business leader and serial entrepreneur Scott Galloway cuts through the biggest stories in ...